Background
swapnil hiremath
MENTOR: Is Rituximab Ripened enough for ...

This week, we will discuss the MENTOR trial, which pitted rituximab versus cyclosporine for membranous nephropathy

MENTOR: Is Rituximab Ripened enough for Membranous?
Background
joel topf
How Long is too Long? Steroids in Nephrotic ...

This week, we will discuss an RCT, a pediatric RCT, and a pediatric RCT in childhood nephrotic syndrome! A trial that asks a question of burning importance to the management of childhood nephrotic syndrome. Join us as we tackle PREDNOS.

How Long is too Long? Steroids in Nephrotic Syndrome
Background
joel topf
SONAR: Is there a Signal in the Noise?

Atrosentan makes a return visit to NephJC, but now it goes beyond changes in proteinuria and shows improved kidney outcomes. Is it enough to overcome the fluid complications?

SONAR: Is there a Signal in the Noise?
Background
swapnil hiremath
Risk Stratifying A Heterogeneous Entity: IgA ...

This week, we will discuss a risk score which helps to prognosticate the most common glomerular disease. Not only is IgA most common - it is quite heterogeneous, which makes the problem of who should get treated quite difficult.

Risk Stratifying A Heterogeneous Entity: IgA Nephropathy
Background
joel topf
Fixing Hypernatremia: Acting Fast or Acting ...

They always said not to correct hypernatremia faster than 0.5 mmol/L/hour but what do they know and who are they anyways? New data questions this ancient dogma.

Fixing Hypernatremia: Acting Fast or Acting Slow?

jama

Kidney Transplant & Race and Ethnicity: Things are Getting Better - Or Are They?

Kidney Transplant & Race and Ethnicity: Things are Getting Better - Or Are They?

This week, we will discuss the JAMA paper on disparities in living donor kidney transplant *rates* across race/ethnicities. There is a parallel paper from the UK, which shows somewhat similar findings. Join us Feb 6 and 7 to discuss on #NephJC!

IgA Nephropathy: Testing Steroids Again

IgA Nephropathy: Testing Steroids Again

Stop-IgAN suggested steroids may not be useful in patients with intermediate range proteinuria. Now, in a different population with more proteinuria, TESTING finds a mixed result: some benfit + more adverse events. Should we keep on TESTING?